Allelic losses at 8p, 10q, 11p, 13q, 16q, 17p, and 18q in prostatic carcinomas: The impact of zonal location, Gleason grade, and tumour multifocality

Prostate Cancer and Prostatic Diseases

Volumn 2, Issue 4, 1999, Pages 204-210

  Erbersdobler, A ^a,b   Graefen, M ^a   Wullbrand, A ^a   Hammerer, P ^a   Henke, R P ^a  

^a UNIVERSITY OF HAMBURG   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Microsatellites; Prostatic neoplasm; Zonal location

Indexed keywords

ADULT; AGED; ARTICLE; CANCER GRADING; CHROMOSOME 10Q; CHROMOSOME 11P; CHROMOSOME 13Q; CHROMOSOME 16Q; CHROMOSOME 17P; CHROMOSOME 18Q; CHROMOSOME 8P; CHROMOSOME ARM; CONTROLLED STUDY; GENE FREQUENCY; GENE LOSS; GENETIC HETEROGENEITY; HUMAN; HUMAN TISSUE; MALE; MOLECULAR GENETICS; MULTIPLE CANCER; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CARCINOMA;

EID: 0033393690     PISSN: 13657852     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500324     Document Type: Article

References (57)

1. McNeal JE et al. Histologic differentiation, cancer volume, and pelvic lymph node metastasis in adenocarcinoma of the prostate. Cancer 1990; 66: 1225-1233.
2. Gleason DF and Veterans Administration Cooperative Urological Research Group. Histological grading and clinical staging of prostate carcinoma. In: Tannenbaum M (ed). Urologic Pathology: The Prostate. Lea and Febiger: Philadelphia, 1977, pp171-197.
3. McNeal JE. Cancer volume and site of origin of adenocarcinoma in the prostate: Relationship to local and distant spread. Hum Pathol 1992; 23: 258-266.
4. McNeal JE, Redwine EA, Freiha FS, Stamey TA. Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread. Am J Surg Pathol 1988; 12: 897-906.
5. Greene DR et al. A comparison of the morphological features of cancer arising in the transition zone and in the peripheral zone of the prostate. J Urol 1991; 146: 1069-1076.
6. Grignon DJ, Sakr WA. Zonal origin of prostatic adenocarcinoma: Are there biologic differences between transition zone and peripheral zone adenocarcinomas of the prostate gland? J Cell Biochem 1994; 19: 267-269.
7. Erbersdobler A, Hammerer P, Huland H, Henke R-P. Numerical chromosomal aberrations in transition-zone carcinomas of the prostate. J Urol 1997; 158: 1594-1598.
8. Reissigl A et al. Frequency and clinical significance of transition zone cancer in prostate cancer screening. Prostate 1997; 30: 130-135.
9. Emmert-Buck MR et al. Allelic loss on chromosome 8p12-21 in microdissected prostate intraepithelial neoplasia. Cancer Res 1995; 55: 2959-2962.
10. Häggman MJ, Wojno KJ, Pearsall CP, Macoska JA. Allelic loss of 8p sequences in prostatic intraepithelial neoplasia and carcinoma. Urology 1997; 50: 643-647.
11. Elo JP et al. Loss of heterozygosity at 16q24.1-q24.2 is significantly associated with metastatic and aggressive behavior of prostate cancer. Cancer Res 1997; 57: 3356-3359.
12. Latil A et al. Loss of heterozygosity at chromosome 16q in prostate adenocarcinoma: Identification of three independent regions. Cancer Res 1997; 57: 1058-1062.
13. Elo JP et al. Three independently deleted regions at chromosome arm 16q in human prostate cancer: allelic loss at 16q24.1 -q24.2 is associated with aggressive behaviour of the disease, recurrent growth, poor differentiation of the tumour and poor prognosis for the patient. Br J Cancer 1999; 79: 156-160.
14. Sakr WA et al. Allelic loss in locally metastatic, multisampled prostate cancer. Cancer Res 1994; 54: 3273-3277.
15. Alers JC et al. Cytogenetic heterogeneity and histologictumor growth patterns in prostatic cancer. Cytometry 1995; 21: 85-94.
16. Cheng L et al. Evidence of independent origin of multiple tumors from patients with prostate cancer. J Natl Cancer Inst 1998; 90: 233-237.
17. Macintosh CA, Stower M, Reid N, Maitland NJ. Precise microdissection of human prostate cancers reveals genotypic heterogeneity. Cancer Res 1998; 58: 23-28.
18. Hügel A, Wernert N. Loss of heterozygosity (LOH), malignancy grade and clonality in microdissected prostate cancer. Br J Cancer 1999; 79: 551-557.
19. Erbersdobler A et al. Microsatellite alterations at chromosomes 9p, 13q, and 17p in nonmuscle-invasive transitional cell carcinomas of the urinary bladder. Oncol Res 1998; 10: 415-420.
20. Von Deimling A, Bender B, Louis DN, Wiestler OD. A rapid and non-radioactive PCR based assay for the detection of allelic loss in human gliomas. Neuropathol Appl Neurobiol 1993; 19: 524-529.
21. MacGrogan D et al. Loss of chromosome arm 8p loci in prostate cancer: Mapping by quantitative allelic imbalance. Genes Chromosom Cancer 1994; 10: 151-159.
22. Takahashi S et al. Frequent loss of heterozygosity at 7q31.1 in primary prostate cancer is associated with tumor aggressiveness and progression. Cancer Res 1995; 55: 4114-4119.
23. Cunningham JM et al. Allelic imbalance and microsatellite instability in prostatic adenocarcinoma. Cancer Res 1996; 56: 4475-4482.
24. Latil A, Fournier G, Cussenot O, Liderau R. Differential chromosome allelic imbalance in the progression of human prostate cancer. J Urol 1996; 156: 2079-2083.
25. Godfrey TE, Cher ML, Chabra V, Jensen RH. Allelic imbalance mapping of chromosome 16 shows two regions of common deletion in prostate adenocarcinoma. Cancer Genet Cytogenet 1997; 98: 36-42.
26. Parker SL, Tong T, Bolden S, Wingo PA. Cancer Statistics, 1997. CA Cancer J Clin 1997; 47: 5-27.
27. Noldus J, Stamey TA. Histological characteristics of radical prostatectomy specimens in men with a serum prostate specific antigen of 4ng/ml or less. J Urol 1996; 155: 441-443.
28. Miller GJ, Cygan JM. Morphology of prostate cancer: The effects of multifocality on histological grade, tumor volume and capsule penetration. J Urol 1994; 152: 1709-1713.
29. Ruijter ET et al. Histological grade heterogeneity in multifocal prostate cancer. Biological and clinical implications. J Pathol 1996; 180: 295-299.
30. Bostwick DG. High grade prostatic intraepithelial neoplasia. The most likely precursor of prostate cancer. Cancer 1995; 75: 1823-1836.
31. Epstein JI. Adenosis (atypical adenomatous hyperplasia). Histopathology and relationship to carcinoma. Path Res Pract 1995; 191: 888-898.
32. Cheng L et al. Atypical adenomatous hyperplasia of the prostate: A premalignant lesion? Cancer Res 1998; 58: 389-391.
33. Bova S et al. Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer. Cancer Res 1993; 53: 3869-3873.
34. Trapman J et al. Loss of heterozygosity of chromosome 8 microsatellite loci implicates a candidate tumour suppressor gene between the loci D8S87 and D8S133 in human prostate cancer. Cancer Res 1994; 54: 6061-6064.
35. Crundwell MC et al. Allelic loss on chromosomes 8p, 22q, and 18q (DCC) in human prostate cancer. Int J Cancer 1996; 69: 295-300.
36. Vocke CD et al. Analysis of 99 microdissected prostate carcinomas reveals a high frequency of allelic loss on chromosome 8p12-21. Cancer Res 1996; 56: 2411-2416.
37. Carter BS et al. Allelic loss of chromosomes 16q and 10q in human prostate cancer. Proc Natl Acad Sci USA 1990; 87: 8751-8755.
38. Trybus TM et al. Distinct areas of allelic loss on chromosomal regions 10p and 10q in human prostate cancer. Cancer Res 1996; 50: 2263-2267.
39. Ittmann MM. Loss of heterozygosity on chromosomes 10 and 17 in clinically localized prostate carcinoma. Prostate 1996; 28: 275-281.
40. Gray IC et al. Loss of chromosomal region 10q23-25 in prostate cancer. Cancer Res 1995; 55: 4800-4803.
41. Cairns P et al. Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res 1997; 57: 4997-5000.
42. Pesche S et al. PTEN/MMAC1/TEP1 involvement in primary prostate cancers. Oncogene 1998; 16: C2879-2883.
43. Ittmann M. Allelic loss on chromosome 10 in prostate adenocarcinoma. Cancer Res 1996; 56: 2143-2147.
44. Dong J-T et al. Down-regulation of the KAI1 metastasis suppressor gene during the progression of human prostatic cancer infrequently involves gene mutation or allelic loss. Cancer Res 1998; 56: 4387-4390.
45. Kawana Y et al. Location of KAI1 on the short arm of human chromosome 11 and frequency of allelic loss in advanced human prostate cancer. Prostate 1997; 32: 205-213.
46. Brooks JD, Bova GS, Isaacs WB. Allelic loss of the retinoblastoma gene in primary human prostatic adenocarcinomas. Prostate 1995; 26: 35-39.
47. Cooney KA et al. Distinct regions of allelic loss on 13q in prostate cancer. Cancer Res 1996; 56: 1142-1145.
48. Edwards SM et al. Immunohistochemical expression of BRCA2 protein and allelic loss at the BRCA2 locus in prostate cancer. Int J Cancer 1998; 78: 1-7.
49. Osman I et al. Chromosome 16 in primary prostate cancer: A microsatellite analysis. Int J Cancer 1997; 71: 580-584.
50. Ittmann M et al. Alterations in the p53 and MDM-2 genes are infrequent in clinically localized, stage B prostate adenocarcinomas. Am J Pathol 1994; 145: 287-293.
51. Mirchandani D et al. Heterogeneity in intratumor distribution of p53 mutations in human prostate cancer. Am J Pathol 1995; 147: 92-101.
52. Terrell RB et al. Microsatellite instability in adenocarcinoma of the prostate. Am J Pathol 1995; 147: 799-805.
53. Villers A, McNeal J, Freiha F, Stamey T. Multiple cancers in the prostate. Morphologic features of clinically recognized versus incidental tumors. Cancer 1992; 70: 2313-2318.
54. Zitzelsberger H et al. Genetic heterogeneity in a prostatic carcinoma and associated prostatic intraepithelial neoplasia as demonstrated by combined use of laser-microdissection, degenerate oligonucleotide primed PCR and comparative genomic hybridization. Virch Arch 1998; 433: 297-304.
55. Greene DR et al. Some small prostate cancers are nondiploid by nuclear image analysis: Correlation of deoxyribonucleic acid ploidy status and pathological features. J Urol 1994; 151: 1301-1307.
56. Crundwell MC, Arkell DG, Gearty J, Phillips SMA. Genetic alterations in incidentally diagnosed, transitional zone prostate cancer: A seven year follow-up. J Urol 1997; 158: 1568-1575.
57. Kibel AS et al. Identification of 12p as a region of frequent deletion in advanced prostate cancer. Cancer Res 1998; 58: 5652-5655.